Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Nitric oxide-releasing NSAIDs: a new dimension in nonsteroidal antiinflammatory drugs
Autore:
Kulkarni, SK; Jain, NK; Singh, A;
Indirizzi:
Panjab Univ, Div Pharmacol, Univ Inst Pharmaceut Sci, Chandigarh 160014, India Panjab Univ Chandigarh India 160014 maceut Sci, Chandigarh 160014, India Panacea Biotec Ltd, Div Res & Dev, Lalru 140501, Punjab, India Panacea Biotec Ltd Lalru Punjab India 140501 Lalru 140501, Punjab, India
Titolo Testata:
DRUGS OF THE FUTURE
fascicolo: 5, volume: 26, anno: 2001,
pagine: 485 - 489
SICI:
0377-8282(200105)26:5<485:NONAND>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
SELECTIVE COX-2 INHIBITORS; GASTROINTESTINAL TOXICITY; IN-VITRO; ANTINOCICEPTIVE ACTIVITY; RELAXING FACTOR; MUCOSAL INJURY; RATS; CYCLOOXYGENASE-2; ASPIRIN; PHARMACOLOGY;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
49
Recensione:
Indirizzi per estratti:
Indirizzo: Kulkarni, SK Panjab Univ, Div Pharmacol, Univ Inst Pharmaceut Sci, Chandigarh 160014, India Panjab Univ Chandigarh India 160014 handigarh 160014, India
Citazione:
S.K. Kulkarni et al., "Nitric oxide-releasing NSAIDs: a new dimension in nonsteroidal antiinflammatory drugs", DRUG FUTURE, 26(5), 2001, pp. 485-489

Abstract

Nonsteroidal antiinflammatory drugs (NSAIDs) are among the most commonly prescribed drugs in the world, but their use as antiinflammatory, antipyretic, antithrombotic and analgesic agents is limited by their adverse effects on the gastrointestinal tract. In recent years, two promising new strategies in the development of NSAIDs that spare the gastrointestinal tract have emerged. First, the development of selective inhibitors of cyclooxygenase-2 (COX-2), the inducible isoform of the prostaglandin G/H synthase enzyme. Since COX-1, the constitutively expressed isoform of COX, has been identifiedin many tissues, it has been suggested that a selective inhibitor of COX-2would suppress prostaglandin synthesis at sites of inflammation but spare the constitutive COX-1 in other tissues, such as the gastrointestinal tract. Although the development of selective COX-2 inhibitors appears to be a rational approach in the evolution of NSAIDs with improved gastrointestinal tolerability, it was recently reported that COX-2 may be important for homeostasis in health and disease. Furthermore, it has been speculated that COX-2 specificity limits the therapeutic use of COX-2 inhibitors; for example, they lack the cardioprotective effects of aspirin which are mediated through COX-1. A more recent approach to reducing the gastrointestinal toxicity of conventional NSAIDs has been the development of nitric oxide (NO)-releasing NSAIDs. Nitric oxide (NO) has been reported to play a critical role in maintaining the integrity of the gastroduodenal mucose and exerts many of the same effects as endogenous prostaglandins. The present article focuses onthe NONSAIDs that have potential clinical applications, as well as some drug candidates now in development.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 11:21:07